Navigation Links
FDA Approves Marketing of RMS Subcutaneous Needle Sets
Date:6/1/2011

CHESTER, N.Y., June 1, 2011 /PRNewswire/ -- Repro-Med Systems, Inc., (REPR.PK) announced today that it has received approval from the Food and Drug Administration (FDA) to begin U.S. marketing of its new Subcutaneous Needle Sets which the company is promoting as the HIgh Flo™ RMS Subcutaneous Needle Sets.  The needle sets are intended for the delivery of medication to subcutaneous tissue.  The needle sets have previously been approved and available for use by patients in Canada and Europe.  Repro-Med Systems, Inc. utilizes the name RMS Medical Products.

"The FDA's approval allows patients here in the U.S., where our products are manufactured, to enjoy the benefits realized currently by many patients overseas," said Andrew I. Sealfon, president of the company, based in Chester, NY.  "Although we use a needle which is smaller in gauge than many needles being used for subcutaneous administration of certain drugs, our design results in flow rates comparable to, or better than, the flow rates of the larger needles.  This can result in less pain and discomfort for the patient, less insertion difficulty for the patient and medical personnel, and shorter infusion times," Sealfon added.

The needle sets are an ideal companion for RMS Medical Products' FREEDOM60® Syringe Infusion System, which has enhanced the lifestyle of numerous patients requiring regular drug infusions due to its portability and ease of use.  FREEDOM60® enjoys widespread use by ambulatory patients at home as well as those in healthcare facilities.  "Even though the RMS Subcutaneous Needle Sets provide advanced fluidics, the pricing will be highly competitive, just as FREEDOM60® has been in the infusion pump market," Sealfon said.

The RMS Subcutaneous Needle Sets use custom designed, approximately 26-gauge needles, which have a smaller outside diameter than commonly used 24-gauge needles.  This translates into less "ouch" when the needles are inserted, and greater comfort throughout lengthy infusions.  The sets have superior fluidics resulting in faster flow rates.  When used in multi-needle sets, as typically is the case for subcutaneous immune globulin infusions, the RMS Subcutaneous Needle Sets distribute equal volumes of drug to all needles.  The sets are available in single, double, triple, and quad configurations.  RMS produces a low residual "Y" connector, which allows up to eight needles to be used for a single infusion.  Needles lengths currently available are 6mm, 9mm, and 12mm.

"We believe that patients who may be fearful of needles, or are uncomfortable with the thought of having to undergo lengthy infusions, will appreciate the potential benefits, as will health care providers," Sealfon concluded.

RMS Medical Products is the manufacturer of the FREEDOM60® Syringe Infusion System and the RES-Q-VAC® hand powered suction device.  A primary use for the FREEDOM60® Syringe Infusion Pump is in subcutaneous administration of immune globulin due to its safe, controlled pressure and ability to adjust automatically to the flow.  The inherently safe pressures used to deliver drugs to patients minimize discomfort, swelling and other complications sometimes found with conventional electric infusion devices.  There are additional applications such as the delivery of antibiotics for the ambulatory patient.

Forward Looking Statements

Statements in this press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  All statements, other than statements of historical facts, may be forward-looking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances.  These statements involve risks and uncertainties that could cause actual results to differ materially from those included in forward-looking statements due to a variety of factors.  More information about these factors can be found in Repro-Med's latest Annual Report filed with Securities and Exchange Commission on Form 10-K.  The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information:
Andrew I. Sealfon, President
RMS Medical Products
24 Carpenter Road, Chester, NY 10918
Telephone: (845) 469-2042
FAX:  (845) 469-5518


'/>"/>
SOURCE Repro-Med Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Injectable Gel to Treat Fecal Incontinence
2. FDA approves Incivek for hepatitis C
3. FDA Approves Sutent for Rare Type of Pancreatic Cancer
4. FDA Approves New HIV Treatment
5. FDA Approves Victrelis for Hepatitis C
6. FDA Approves New Treatment for Rare Type of Pancreatic Cancer
7. FDA Approves Novartis Drug Afinitor to Treat Pancreatic Neuroendocrine Tumors
8. FDA Approves Tradjenta™ (linagliptin) Tablets for the Treatment of Type 2 Diabetes
9. FDA Approves New Treatment for Type 2 Diabetes
10. FDA Approves Zytiga for Late-Stage Prostate Cancer
11. FDA Approves Updated, Clarified Indication for Use for iFuse Implant System®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... 20, 2017  Today from HIMSS17, Ambra Health ... suite, announced the launch of  Ambra for Developers ... Built around modern, RESTful web-services, this is the first ... With these new APIs, IT departments at health ... data into other applications such as population health or ...
(Date:2/20/2017)... Research and Markets has announced the addition ... and Trends - Product (RFID refrigerators and RFID freezers), Application (Diagnostic ... to their offering. ... The Global RFID Blood Refrigerator and Freezer Market is poised ... 2025. This industry report analyzes the global markets ...
(Date:2/20/2017)... PUNE, India , February 20, 2017 According ... Formulation (Type (Solution, Suspension, Dry powder), Device Type (Metered dose, Dry Powder, ... to 2021" published by MarketsandMarkets, The market is projected to reach USD ... CAGR of 6.5% during the forecast period. ... ...
Breaking Medicine Technology:
(Date:2/20/2017)... ... February 20, 2017 , ... Today, Illuma ... plan partners, announced during the 2017 Annual HIMSS Conference & Exhibition ... for diabetic patients and integrating eye care into mainstream healthcare delivery is powered ...
(Date:2/19/2017)... ... February 19, 2017 , ... The Citadel’s new Swain Department ... being led by Amelia Joseph, Ph.D. Joseph was engaged by the college as a ... department in early 2016. After a nation-wide search, she was selected to head the ...
(Date:2/19/2017)... ... February 19, 2017 , ... ProBrand Glitch is a set of 30 glitch distortion logo reveals ... easily reveal any logo with a glitch reveal in just a few clicks of a ... and animation of each preset. Use these presets to add a uniquely animated logo to ...
(Date:2/19/2017)... ... February 19, 2017 , ... Orbita, ... join forces with Healthwise ® at HIMSS 2017 to showcase ... in evidence-based health education, technology and services, will demonstrate a voice-powered knowedge assistant ...
(Date:2/18/2017)... ... February 17, 2017 , ... Focused start-ups, not traditional health ... according to the recent NEJM Catalyst Insights Report on the New Marketplace. ... Insights Council, a qualified group of U.S. executives, clinical leaders, and clinicians at ...
Breaking Medicine News(10 mins):